

# Agnes Y Y Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9906092/publications.pdf>

Version: 2024-02-01

81  
papers

8,668  
citations

147566

31  
h-index

74018

75  
g-index

82  
all docs

82  
docs citations

82  
times ranked

7121  
citing authors

#	ARTICLE	IF	CITATIONS
1	How I treat and prevent venous thrombotic complications in patients with lymphoma. <i>Blood</i> , 2022, 139, 1489-1500.	0.6	5
2	Cancer-associated venous thromboembolism. <i>Nature Reviews Disease Primers</i> , 2022, 8, 11.	18.1	130
3	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 11, 100228.	1.5	2
4	Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination. <i>Blood Advances</i> , 2022, 6, 3315-3320.	2.5	5
5	Unanswered questions in cancer-associated thrombosis. <i>British Journal of Haematology</i> , 2022, 198, 812-825.	1.2	11
6	Vaccine-induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	2
7	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. <i>Blood Reviews</i> , 2021, 45, 100707.	2.8	137
8	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021, 5, 927-974.	2.5	431
9	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) <i>Tj ETQq1 1 0,784314 rgBT /Ove Trials</i> , 2021, 22, 202.	0.7	19
10	Annals for Hospitalists Inpatient Notes - Direct Oral Anticoagulants in Patients With Cancer "What Hospitalists Need to Know. <i>Annals of Internal Medicine</i> , 2021, 174, HO2-HO3.	2.0	0
11	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021, 96, 102190.	3.4	14
12	Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation. <i>JACC: CardioOncology</i> , 2021, 3, 425-427.	1.7	6
13	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism "The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.	0.8	10
14	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ</i> , The, 2021, 375, n2400.	3.0	250
15	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	1.0	39
16	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. <i>Current Oncology</i> , 2021, 28, 5434-5451.	0.9	26
17	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	0.8	971
18	Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 154-160.	1.0	26

#	ARTICLE	IF	CITATIONS
19	The changing landscape of anticoagulation in cancer-associated thrombosis. <i>Blood Advances</i> , 2020, 4, 969-969.	2.5	0
20	Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. <i>Thrombosis Research</i> , 2020, 188, 106-114.	0.8	19
21	Anticoagulant Therapy for Venous Thromboembolism in Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1650-1652.	13.9	25
22	Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor cell cytokine release syndrome. <i>British Journal of Haematology</i> , 2020, 190, e150-e154.	1.2	32
23	Anticoagulation practice patterns in COVID-19: A global survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 969-983.	1.0	35
24	A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 702-713.	1.8	42
25	Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020, 27, e32-e55.	1.9	4
26	Direct Oral Anticoagulants in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 638-647.	1.5	7
27	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
28	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 711-719.	13.9	614
29	Update from the clinic: what's new in the diagnosis of cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 167-174.	0.9	9
30	Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 914-921.	1.8	37
31	What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life? Value in Health, 2018, 21, 449-455.	0.1	58
32	Overview of VTE treatment in cancer according to clinical guidelines. <i>Thrombosis Research</i> , 2018, 164, S162-S167.	0.8	14
33	COSIMO—patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.	0.9	20
34	Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 386-392.	1.0	18
35	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669.	1.0	47
36	Thromboprophylaxis in Cancer Patients Undergoing Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 672-681.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologist and Hematologist Respondents in a Canadian Survey. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 116-119.	0.3	6
38	When can we stop anticoagulation in patients with cancer-associated thrombosis?. <i>Blood</i> , 2017, 130, 2484-2490.	0.6	21
39	When can we stop anticoagulation in patients with cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 128-135.	0.9	15
40	Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1078-1085.	0.8	60
41	Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol. <i>BMJ Open</i> , 2016, 6, e013263.	0.8	4
42	Tinzaparin vs Warfarin for Acute Venous Thromboembolism—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 200.	3.8	0
43	Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. <i>Blood Reviews</i> , 2016, 30, 411-420.	2.8	236
44	Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology. <i>Thrombosis Research</i> , 2016, 140, S119-S127.	0.8	10
45	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 81-91.	1.0	169
46	Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1422-1430.	0.7	97
47	Incidence and Outcomes of Catheter Related Thrombosis in Acute Leukemia: Single Centre Experience. <i>Blood</i> , 2016, 128, 3828-3828.	0.6	0
48	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. <i>Blood</i> , 2015, 126, 597-603.	0.6	101
49	Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. <i>Annals of Hematology</i> , 2015, 94, 329-336.	0.8	65
50	Novel or Non—Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 237-243.	1.5	7
51	Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.	1.6	133
52	Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 677.	3.8	530
53	Prevention and treatment of venous thromboembolism in patients with cancer. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 312-317.	0.9	7
54	Management of incidental splanchnic vein thrombosis in cancer patients. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 318-320.	0.9	8

#	ARTICLE	IF	CITATIONS
55	D-Dimer Levels as a Marker of Cutaneous Disease Activity. JAMA Dermatology, 2014, 150, 880.	2.0	9
56	Venous Thromboembolism in Older Adults: A Community-based Study. American Journal of Medicine, 2014, 127, 530-537.e3.	0.6	41
57	Thromboprophylaxis in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2014, 40, 395-400.	1.5	7
58	Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. Thrombosis Research, 2014, 133, S167-S171.	0.8	17
59	Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. Thrombosis Research, 2014, 134, 300-304.	0.8	18
60	Treatment of cancer-associated thrombosis. Blood, 2013, 122, 2310-2317.	0.6	158
61	Treatment of established thrombotic events in patients with cancer. Thrombosis Research, 2012, 129, S146-S153.	0.8	32
62	Catheter-related thrombosis: lifeline or a pain in the neck?. Hematology American Society of Hematology Education Program, 2012, 2012, 638-644.	0.9	38
63	Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants. Hematology American Society of Hematology Education Program, 2010, 2010, 144-149.	0.9	52
64	The roles of anticoagulants in patients with cancer. Thrombosis Research, 2010, 125, S8-S11.	0.8	9
65	Treatment of Venous Thrombosis. Cancer Treatment and Research, 2009, 148, 243-257.	0.2	0
66	Treatment of venous thromboembolism in cancer patients. Best Practice and Research in Clinical Haematology, 2009, 22, 93-101.	0.7	9
67	VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment. Thrombosis Research, 2008, 123, S50-S54.	0.8	21
68	Prevention of Deep Vein Thrombosis in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2007, 33, 699-706.	1.5	1
69	The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thrombosis Research, 2007, 120, S121-S127.	0.8	20
70	Thrombosis and Cancer: The Role of Screening for Occult Cancer and Recognizing the Underlying Biological Mechanisms. Hematology American Society of Hematology Education Program, 2006, 2006, 438-443.	0.9	37
71	Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. Journal of Clinical Oncology, 2006, 24, 1404-1408.	0.8	274
72	The role of low-molecular-weight heparins in treating thrombosis. The Journal of Supportive Oncology, 2006, 4, 123-4.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Venous thromboembolism and cancer: prevention and therapy. Vnitri Lekarstvi, 2006, 52 Suppl 1, 127-8, 130-1.	0.1	2
74	Management of thrombosis in cancer: primary prevention and secondary prophylaxis. British Journal of Haematology, 2005, 128, 291-302.	1.2	97
75	Treatment of Venous Thromboembolism in Cancer Patients. Cancer Control, 2005, 12, 17-21.	0.7	17
76	Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2003, 349, 146-153.	13.9	2,344
77	Epidemiology and management of venous thromboembolism in patients with cancer. Thrombosis Research, 2003, 110, 167-172.	0.8	76
78	Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation, 2003, 107, 171-21.	1.6	521
79	Anti-thrombotic therapy in cancer patients. Expert Opinion on Pharmacotherapy, 2003, 4, 2213-2220.	0.9	8
80	The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Current Opinion in Pulmonary Medicine, 2003, 9, 351-355.	1.2	14
81	Diagnosis and Treatment of Venous Thromboembolism. Annual Review of Medicine, 2002, 53, 15-33.	5.0	26